Clinical Trials Logo

Filter by:
NCT ID: NCT05452174 Terminated - Pregnancy Clinical Trials

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

ESNAP
Start date: June 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this proposal is to conduct an early Phase 2 clinical trial to determine the acceptability, dosing, tolerability and safety of mirtazapine for severe nausea and vomiting of pregnancy (sNVP) that is not adequately responsive to current standard treatments. This plan mirrors clinical practice since commonly prescribed antiemetic/ antinauseant drugs will be tested for efficacy before treating with mirtazapine.

NCT ID: NCT05451693 Terminated - Dementia Clinical Trials

Outreach-ER: A Dementia Care Intervention Program

Start date: September 8, 2022
Phase:
Study type: Observational

This is a feasibility/pilot, prospective cohort study to determine how to implement and refine Outreach-ER intervention for a larger clinical study. A key feature of Outreach-ER is to reach out to people living with dementia (PLWD) and their families following an emergency room visit or hospitalization. The outcome of this study will help in the overall goal of studying the impact of Outreach-ER in a larger clinical study and focus on outcomes relevant to PLWD and their care partners.

NCT ID: NCT05450952 Terminated - Stress Clinical Trials

Evaluate the Effects of a Theanine Formulation on Stress, Burnout, Mood, and Sleep in Individuals Who Report Occasional Moderate or High Levels of Stress

Start date: April 21, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effectiveness and safety of the theanine formulation on stress, burnout, mood, and sleep in male and female subjects who are generally healthy

NCT ID: NCT05446168 Terminated - Parkinson Disease Clinical Trials

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

BUTTER
Start date: July 1, 2022
Phase: Phase 1
Study type: Interventional

Small exploratory open-label pilot study to assess the short-chain fatty acid (SCFA) prodrug tributyrin as a potential therapy for persons with Parkinson disease

NCT ID: NCT05446129 Terminated - Colorectal Cancer Clinical Trials

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

Start date: September 27, 2022
Phase: Phase 1
Study type: Interventional

This study is open to people with newly diagnosed colorectal cancer. People who are scheduled for surgery can participate. People either get a medicine called BI 765063 combined with ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. The tested medicines in this study are antibodies that may help the immune system fight cancer. The purpose of this study is to find out how well people with early colorectal cancer can tolerate treatment with these medicines. The study also looks at whether the tumor changes. Participants are put into 2 groups. One group gets ezabenlimab and BI 765063. The other group gets pembrolizumab and BI 765063. All participants receive the study medicines as 2 subsequent infusions into a vein on a single day. Participants are in the study for about 4 months. During this time, they visit the study site about 5 times. The doctors check the health of the participants and note any health problems that could have been caused by ezabenlimab, pembrolizumab, or BI 765063. The doctors also check whether these health problems lead to a delay of the planned surgery.

NCT ID: NCT05445869 Terminated - Clinical trials for Obstructive Sleep Apnea

Severe OSA Study (SOS)

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

This study is a prospective, multi-center, single-arm, open-label study evaluating the safety and effectiveness of therapy with the ProSomnus EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea.

NCT ID: NCT05445596 Terminated - Clinical trials for Intellectual Disability

Improving Treatment for Children With Intellectual and Developmental Disabilities and Problem Behavior in Schools

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Children with intellectual and developmental disabilities (IDDs) often engage in problem behavior, and functional communication training (FCT) is a commonly used treatment for problem behavior in clinical settings. During FCT, children learn prosocial ways to request functional reinforcers (e.g., "their way") instead of using problem behavior. For example, a child who engages in self-injury to escape math instruction may be taught to exchange a break picture card to receive a brief break from the math task as an alternative to self-injury. While the efficacy of FCT is well established, less is known about its effects in school settings when procedures are necessarily adapted for feasibility. The purpose of this investigation is to develop and evaluate methods for implementing FCT for children with IDDs in school settings. The investigators will use single case experimental design, in which each participant will serve as their own control, to address the research questions. First, the investigators will evaluate the effects of providing higher quality, longer duration reinforcement for appropriate requests relative to problem behavior (e.g., 1-minute break with a preferred activity versus 20-s break alone) during FCT compared to providing equal reinforcement for appropriate requests and problem behavior. Next, the investigators will develop a treatment extension to teach children to complete academic work to gain access to their way. The investigators will use visual cues, such as a green and red index card to teach children when it is time to work and when they may access their way. The investigators will evaluate the effects of the treatment extension on academic work completion, appropriate requests, and problem behavior. Finally, the investigators will examine how visual cues influence children's behavior when educators implement intervention across different academic activities. The investigators will measure the extent to which educators implement programmed intervention procedures to inform treatment feasibility.

NCT ID: NCT05445128 Terminated - Sickle Cell Disease Clinical Trials

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Start date: June 24, 2022
Phase: Phase 2
Study type: Interventional

This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.

NCT ID: NCT05442775 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

COURAGE OLE
Start date: July 25, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also known as COURAGE-ALS)

NCT ID: NCT05441826 Terminated - Clinical trials for Focal Segmental Glomerulosclerosis

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Start date: May 3, 2022
Phase: Phase 2
Study type: Interventional

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.